In July 2025, Inovio Pharmaceuticals conducted a Phase 1/2 trial to evaluate safety, immunogenicity and preliminary efficacy ...

This was the stock's second consecutive day of losses.

Biogen will invest an extra $2 billion to expand its RTP facilities, focusing on AI-driven manufacturing and late-stage ...

A new genetic test, based on data from more than five million people, can identify people at risk of severe obesity. The test can be performed on children before their genetic risk starts to shape ...

Icotrokinra is a first-in-class targeted oral peptide that blocks interleukin (IL) 23 and its receptor, which plays a key role in the inflammatory response in plaque psoriasis.

Bristol-Myers Squibb Company (NYSE:BMY) is one of the largest and most well-known American pharmaceutical companies.

Bristol Myers Squibb said the U.S. Food and Drug Administration has accepted its application seeking expanded approval of its plaque psoriasis drug Sotyktu for the treatment of adults with active ...

Bristol Myers Squibb is making progress paying down debt from prior deals and improving financial flexibility so it can make ...

Bristol Myers Squibb & Co. (NYSE:BMY) on Friday announced topline results from the Phase 3 INDEPENDENCE trial evaluating ...

Bristol-Myers Squibb Company (NYSE: BMY) is one of the best cheap stocks under $50 to buy now. In a report released on July ...

Pfizer and Bristol Myers Squibb have launched a direct-to-patient program offering their blood thinner Eliquis at a 40% discount for cash-paying patients.  The list price for Eliquis (apixaban) is ...

An Omnicom spokesperson confirmed that the 2025 MM+M Agency 100 honoree will soon be folded into Omnicom Health subsidiaries.